by Hong Kong Baptist University A research team led by Hong Kong Baptist University (HKBU) has developed a novel anti-Epstein-Barr virus (EBV) drug that can selectively disrupt a viral protein produced by EBV, leading to the shrinkage of tumors caused by the virus. It is the first known agent to successfully target the virus and...
A world-first clinical trial of a new cellular immunotherapy for multiple sclerosis (MS) has improved symptoms and quality of life for the majority of patients. The treatment targets the Epstein-Barr virus (EBV), and is based on a theory formulated by University of Queensland and Royal Brisbane and Women’s Hospital (RBWH) researcher Professor Michael Pender. This...
